Co-infection of SARS-COV-2 and Influenza A Virus: A Case Series and Fast Review

Abstract

Coronavirus disease 2019 (COVID-19) occurs in the influenza season and has become a global pandemic. The present study aimed to examine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with influenza A virus (IAV) in an attempt to provide clues for the antiviral interventions of co-infected patients. We described two patients who were co-infected with SARS-CoV-2 and IAV treated at Wuhan Union Hospital, China. In addition, we performed a review in PubMed, Web of Science and CNKI (from January 1 up to November 1, 2020) with combinations of the following key words: “COVID-19, SARS-COV-2, influenza A and co-infection”. A total of 28 co-infected patients were enrolled in the analysis. Of the 28 patients, the median age was 54.5 years (IQR, 34.25–67.5) and 14 cases (50.0%) were classified as severe types. The most common symptoms were fever (85.71%), cough (82.14%) and dyspnea (60.71%). Sixteen patients had lymphocytopenia on admission and 23 patients exhibited abnormal radiological changes. The median time from symptom onset to hospital admission was 4 days (IQR, 3–6), and the median time of hospital stay was 14 days (IQR, 8.5–16.75). In conclusion, patients with SARS-COV-2 and IAV co-infection were similar to those infected with SARS-COV-2 alone in symptoms and radiological images. SARS-COV-2 co-infection with IAV could lead to more severe clinical condition but did not experience longer hospital stay compared with patients infected with SARS-COV-2 alone.

Keywords

co-infection / COVID-19 / influenza A / SARS-COV-2

References

[1] LuR, ZhaoX, LiJ, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 395(10224): 565-574

[2] WangD, HuB, HuC, et al.. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061

[3] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[4] Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology, 2020:200230

[5] ZhangR, OuyangH, FuL, et al.. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol, 2020, 30(8): 4417-4426

[6] ThompsonWW. Influenza-Associated Hospitalizations in the United States. JAMA, 2004, 292(11): 1333

[7] LafondKE, NarrH, RasoolyMH, et al.. Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis. Plos Med, 2016, 13(3): e1001977

[8] CollinsJP, CampbellAP, OpenoK, et al.. Clinical Features and Outcomes of Immunocompromised Children Hospitalized with Laboratory-Confirmed Influenza in the United States, 2011–2015. J Pediat Inf Dis Soc, 2019, 8(6): 539-549

[9] ErcenDO, ArslanS, AkdoganO, et al.. Clinical, radiological and prognostic features of influenza cases in the influenza epidemic during years 2016–2017. Tuberk Toraks, 2018, 66(2): 144-199

[10] McCullersJA. Insights into the Interaction between Influenza Virus and Pneumococcus. Clin Microbiol Rev, 2006, 19(3): 571-582

[11] Martin-LoechesI, J, SchultzM, VincentJ, et al.. Increased incidence of co-infection in critically ill patients with influenza. Intens Care Med, 2017, 43(1): 48-58

[12] DingQ, LuP, FanY, et al.. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol, 2020, 92(9): 1549-1555

[13] WuX, CaiY, HuangX, et al.. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis, 2020, 26(6): 1324-1326

[14] KhodamoradiZ, MoghadamiM, LotfiM. Co-infection of Coronavirus Disease 2019 and Influenza A: A Report from Iran. Arch Iran Med, 2020, 23(4): 239-243

[15] National Health Commission, State Administration of Traditional Chinese Medicine. Diagnosis and Treatment of Protocol of COVID-19. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.Shtml, 2020-03-03

[16] UyekiTM. Influenza. Ann Intern Med, 2017, 167(5): C33-C48

[17] ShaGJ. Co-infection of SARS CoV-2 and influenza A in a child: a case report. Henan J Prev Med (Chinese), 2020, 31(05): 323-324

[18] KonalaVM, AdapaS, NaramalaS, et al.. A Case Series of Patients Coinfected With Influenza and COVID-19. J Investig Med High Impact Case Rep, 2020, 8: 1562230171

[19] D’AbramoA, LeporeL, PalazzoloC, et al.. Acute respiratory distress syndrome due to SARS-CoV-2 and Influenza A co-infection in an Italian patient: Minireview of the literature. Int J Infect Dis, 2020, 97: 236-239

[20] PongpirulWA, MottJA, WoodringJV, et al.. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand. Emerg Infect Dis, 2020, 26(7): 1580-1585

[21] WehlG, LaibleM, RauchenzaunerM. Co-infection of SARS CoV-2 and influenza A in a Pediatric Patient in Germany. Klin Padiatr, 2020, 232(4): 217

[22] ZhengX, WangH, SuZ, et al.. Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China. J Infect, 2020, 81(2): e128-e129

[23] HashemiSA, SafamaneshS, GhafouriM, et al.. Co-infection with COVID-19 andinfluenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran. J Med Virol, 2020, 92(11): 2319-2321

[24] KonalaVM, AdapaS, GayamV, et al.. Co-infection with Influenza A and COVID-19. European J Case Rep Intern Med, 2020, 7(5): 1

[25] AzekawaS, NamkoongH, MitamuraK, et al.. Co-infection with SARS-CoV-2 and influenza A virus. IDCases, 2020, 20: e775

[26] SinghB, KaurP, ReidR, et al.. COVID-19 and Influenza Co-Infection: Report of Three Cases. Cureus, 2020, 12(8): e9852

[27] OzarasR, CirpinR, DuranA, et al.. Influenza and COVID-19 coinfection: Report of six cases and review of the literature. J Med Virol, 2020, 92(11): 2657-2665

[28] Cuadrado-PayánE, Montagud-MarrahiE, Torres-ElorzaM, et al.. SARS-CoV-2 and influenza virus co-infection. Lancet, 2020, 395(10236): e84

[29] KakuyaF, OkuboH, FujiyasuH, et al.. The First Pediatric Patients with Coronavirus Disease 2019 (COVID-19) in Japan: Risk of Co-Infection with Other Respiratory Viruses. Jpn J Infect Dis, 2020, 73(5): 377-380

[30] GokaE, VallelyP, MuttonK, et al.. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. Influenza Other Resp, 2013, 7(6): 1079-1087

[31] MeskillSD, RevellPA, ChandramohanL, et al.. Prevalence of co-infection between respiratory syncytial virus and influenza in children. Am J Emerg Med, 2017, 35(3): 495-498

[32] GuanW, NiZ, HuY, et al.. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med, 2020, 382(18): 1708-1720

[33] HashemiSA, SafamaneshS, Ghasemzadeh-MoghaddamH, et al.. High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran. J Med Virol, 2020, 93: 1008-1012

[34] XuK, ChenY, YuanJ, et al.. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis, 2020, 71(15): 799-806

[35] DobsonJ, WhitleyRJ, PocockS, et al.. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet, 2015, 385(9979): 1729-1737

[36] PinkyL, DobrovolnyHM. SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial?. J Med Virol, 2020, 92(11): 2623-2630

[37] European Centre For Disease Control. Scientific-advice-neuraminidase-inhibitors-2017. https://www.ecdc.europa.eu/sites/default/files/documents/Scientific-advice-neuraminidase-inhibitors-2017.

[38] Centers for Disease Control and Prevention. Influenza, https://www.cdc.gov/flu/treatment/whatyoushould.htm

[39] McCullersJA, BartmessKC. Role of Neuraminidase in Lethal Synergism between Influenza Virus and Streptococcus pneumoniae. J Infect Dis, 2003, 187(6): 1000-1009

[40] ArabiYM, MandourahY, Al-HameedF, et al.. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Resp Crit Care, 2018, 197(6): 757-767

[41] StockmanLJ, BellamyR, GarnerP. SARS: systematic review of treatment effects. Plos Med, 2006, 3(9): e343

[42] NowakMD, SordilloEM, GitmanMR, et al.. Coinfection in SARS-CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus?. J Med Virol, 2020, 92(10): 1699-1700

[43] KimD, QuinnJ, PinskyB, et al.. Rates of Co-infection between SARS-CoV-2 and Other Respiratory Pathogens. JAMA, 2020, 323(20): 2085-2086

[44] Schultz-CherryS. Viral Interference: The Case of Influenza Viruses. J Infect Dis, 2015, 212(11): 1690-1691